Phio Pharmaceuticals Corp. PHIO
We take great care to ensure that the data presented and summarized in this overview for Phio Pharmaceuticals Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PHIO
View allLatest Institutional Activity in PHIO
Top Purchases
Top Sells
About PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Insider Transactions at PHIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2024
|
Jonathan E Freeman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+50.0%
|
-
|
|
Sep 11
2024
|
Robert M. Infarinato VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+21.43%
|
-
|
|
Sep 11
2024
|
Robert J Bitterman Chairman, Pres & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+46.5%
|
-
|
|
Sep 11
2024
|
Patricia A Bradford Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
-
|
|
Sep 11
2024
|
Robert L Ferrara Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Sep 11
2024
|
Curtis Lockshin Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Aug 13
2024
|
Robert M. Infarinato VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+50.0%
|
-
|
|
Jun 07
2024
|
Robert J Bitterman Chairman, Pres & CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+4.55%
|
$0
$0.74 P/Share
|
|
Jun 06
2024
|
Robert J Bitterman Chairman, Pres & CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+4.76%
|
$0
$0.75 P/Share
|
|
Mar 01
2024
|
Caitlin Kontulis Secretary & VP Finance & Admin |
SELL
Payment of exercise price or tax liability
|
Direct |
335
-3.05%
|
$0
$0.96 P/Share
|
|
Feb 26
2024
|
Robert J Bitterman Chairman, Pres & CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+11.63%
|
$0
$0.91 P/Share
|
|
Feb 20
2024
|
Robert J Bitterman Chairman, Pres & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,804
-9.86%
|
$0
$0.76 P/Share
|
|
Feb 17
2024
|
Caitlin Kontulis Secretary & VP Finance & Admin |
SELL
Payment of exercise price or tax liability
|
Direct |
523
-4.55%
|
$0
$0.66 P/Share
|
|
Feb 15
2024
|
Caitlin Kontulis Secretary & VP Finance & Admin |
SELL
Payment of exercise price or tax liability
|
Direct |
658
-5.41%
|
$0
$0.65 P/Share
|
|
Oct 01
2023
|
Robert J Bitterman Chairman, Pres & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
917
-4.77%
|
$917
$1.51 P/Share
|
|
Jul 01
2023
|
Robert J Bitterman Chairman, Pres & CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+4.95%
|
$2,000
$2.84 P/Share
|
|
Jun 30
2023
|
Robert J Bitterman Chairman, Pres & CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+5.21%
|
$2,000
$2.88 P/Share
|
|
Jun 14
2023
|
Robert L Ferrara Director |
BUY
Open market or private purchase
|
Direct |
2,000
+25.0%
|
$6,000
$3.1 P/Share
|
|
Mar 01
2023
|
Caitlin Kontulis Secretary & VP Finance & Admin |
SELL
Payment of exercise price or tax liability
|
Direct |
335
-2.68%
|
$1,675
$5.49 P/Share
|
|
Feb 20
2023
|
Robert J Bitterman Chairman, Pres & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+38.99%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 47.5K shares |
|---|---|
| Open market or private purchase | 4.5K shares |
| Payment of exercise price or tax liability | 3.32K shares |
|---|